NEULANDLAB.NS Profit & Loss
Neuland Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:40
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹1,191.20 Cr. | ₹1,558.58 Cr. | ₹1,476.84 Cr. | ₹2,022.99 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹9.75 Cr. | ₹12.54 Cr. | ₹20.51 Cr. | ₹30.17 Cr. | OtherIncome |
| Total Income | ₹1,200.95 Cr. | ₹1,571.12 Cr. | ₹1,497.35 Cr. | ₹2,053.15 Cr. | Income |
| Cost of Materials Consumed | ₹487.74 Cr. | ₹632.43 Cr. | ₹574.81 Cr. | ₹819.76 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-9.51 Cr. | ₹-55.14 Cr. | ₹12.83 Cr. | ₹-64.26 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹201.79 Cr. | ₹257.06 Cr. | ₹272.00 Cr. | ₹341.14 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹13.07 Cr. | ₹14.00 Cr. | ₹8.30 Cr. | ₹23.95 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹52.78 Cr. | ₹59.70 Cr. | ₹65.55 Cr. | ₹91.74 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹239.34 Cr. | ₹261.65 Cr. | ₹293.93 Cr. | ₹351.84 Cr. | OtherExpenses |
| Total Expenses | ₹985.20 Cr. | ₹1,169.69 Cr. | ₹1,227.42 Cr. | ₹1,564.17 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹215.75 Cr. | ₹401.44 Cr. | ₹269.93 Cr. | ₹488.98 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹76.40 Cr. | ₹0.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹215.75 Cr. | ₹401.44 Cr. | ₹346.33 Cr. | ₹488.98 Cr. | ProfitBeforeTax |
| Tax Expense | ₹52.23 Cr. | ₹101.36 Cr. | ₹86.22 Cr. | ₹124.98 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹163.52 Cr. | ₹300.08 Cr. | ₹260.11 Cr. | ₹364.00 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | ₹0.00 Cr. | ₹0.00 Cr. | ₹364.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from NEULANDLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).